{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:41:22Z","timestamp":1787121682695,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10549-018-5058-6","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T01:18:39Z","timestamp":1543540719000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["A real-world study of cardiac events in >\u20093700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study"],"prefix":"10.1007","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3320-9487","authenticated-orcid":false,"given":"Elisabet","family":"Lidbrink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chmielowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Otremba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bouhlel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Liste Hermoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"N\u00fcesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"5058_CR1","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672. \n                    https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"key":"5058_CR2","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684. \n                    https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"key":"5058_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"key":"5058_CR4","unstructured":"Roche Registration Ltd. Herceptin\u00ae (trastuzumab). Summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000278\/WC500074922.pdf\n                    \n                  . Accessed Sep 2018"},{"key":"5058_CR5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 Years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195\u20131205. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2","journal-title":"Lancet"},{"key":"5058_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","volume":"382","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2\u00a0Years versus 1\u00a0year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382:1021\u20131028. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)61094-6","journal-title":"Lancet"},{"key":"5058_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD et al (2007) 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29\u201336. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)60028-2","journal-title":"Lancet"},{"key":"5058_CR8","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ et al (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366\u20133373. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.35.0868","journal-title":"J Clin Oncol"},{"key":"5058_CR9","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","volume":"28","author":"M Procter","year":"2010","unstructured":"Procter M, Suter TM, de Azambuja E et al (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28:3422\u20133428. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.26.0463","journal-title":"J Clin Oncol"},{"key":"5058_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","volume":"34","author":"PP Advani","year":"2016","unstructured":"Advani PP, Ballman KV, Dockter TJ et al (2016) Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol 34:581\u2013587. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.61.8413","journal-title":"J Clin Oncol"},{"key":"5058_CR11","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","volume":"32","author":"E Azambuja de","year":"2014","unstructured":"de Azambuja E, Procter MJ, van Veldhuisen DJ et al (2014) Trastuzumab-associated cardiac events at 8\u00a0years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol 32:2159\u20132165. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.53.9288","journal-title":"J Clin Oncol"},{"key":"5058_CR12","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"EH Romond","year":"2012","unstructured":"Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792\u20133799. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.40.0010","journal-title":"J Clin Oncol"},{"key":"5058_CR13","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"E Tan-Chiu","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811\u20137819. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.02.4091","journal-title":"J Clin Oncol"},{"key":"5058_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE et al (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231\u20131238. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.13.5467","journal-title":"J Clin Oncol"},{"key":"5058_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Cioffi G, Gori S et al (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18:113\u2013119. \n                    https:\/\/doi.org\/10.1016\/j.cardfail.2011.10.015","journal-title":"J Card Fail"},{"key":"5058_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4048\/jbc.2014.17.4.363","volume":"17","author":"J Xue","year":"2014","unstructured":"Xue J, Jiang Z, Qi F et al (2014) Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study. J Breast Cancer 17:363\u2013369. \n                    https:\/\/doi.org\/10.4048\/jbc.2014.17.4.363","journal-title":"J Breast Cancer"},{"key":"5058_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1056\/NEJMc070065","volume":"357","author":"HL McArthur","year":"2007","unstructured":"McArthur HL, Chia S (2007) Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 357:94\u201395. \n                    https:\/\/doi.org\/10.1056\/NEJMc070065","journal-title":"N Engl J Med"},{"key":"5058_CR18","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","volume":"31","author":"M Chavez-MacGregor","year":"2013","unstructured":"Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222\u20134228. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.48.7884","journal-title":"J Clin Oncol"},{"key":"5058_CR19","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A et al (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504\u20132512. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2012.07.068","journal-title":"J Am Coll Cardiol"},{"key":"5058_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-013-2732-6","volume":"142","author":"G Fried","year":"2013","unstructured":"Fried G, Regev T, Moskovitz M (2013) Trastuzumab-related cardiac events in the treatment of early breast cancer. Breast Cancer Res Treat 142:1\u20137. \n                    https:\/\/doi.org\/10.1007\/s10549-013-2732-6","journal-title":"Breast Cancer Res Treat"},{"key":"5058_CR21","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1200\/JCO.2015.65.1505","volume":"34","author":"P Thavendiranathan","year":"2016","unstructured":"Thavendiranathan P, Abdel-Qadir H, Fischer HD et al (2016) Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study. J Clin Oncol 34:2239\u20132246. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.65.1505","journal-title":"J Clin Oncol"},{"key":"5058_CR22","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/annonc\/mds127","volume":"23","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Gori S, Faggiano P et al (2012) Adjuvant trastuzumab cardiotoxicity in patients over 60\u00a0years of age with early breast cancer: a multicenter cohort analysis. Ann Oncol 23:3058\u20133063. \n                    https:\/\/doi.org\/10.1093\/annonc\/mds127","journal-title":"Ann Oncol"},{"key":"5058_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/sim.4780100409","volume":"10","author":"H Petri","year":"1991","unstructured":"Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577\u2013581. \n                    https:\/\/doi.org\/10.1002\/sim.4780100409","journal-title":"Stat Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-5058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-5058-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-5058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T19:21:22Z","timestamp":1575055282000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-5058-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["5058"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-5058-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The OHERA study was sponsored by F. Hoffmann-La Roche Ltd., Basel, Switzerland. Dr. Lidbrink reports Consultancy\/Advisory role for F. Hoffmann-La Roche. Dr. Chmielowska reports research funding from F. Hoffmann-La Roche. Dr. Bouhlel, Mr. Liste Hermoso, and Dr. N\u00fcesch are employees of F. Hoffmann-La Roche Ltd. Dr. Bouhlel and Dr. N\u00fcesch report stock in F. Hoffmann-La Roche Ltd. Dr. Lauer reports consultancy for F. Hoffmann-La Roche Ltd. Dr. Shing was an employee of Genentech, Inc., at the time of this study and reports remuneration and consultancy for Genentech, Inc. Dr. Misra reports Consultancy\/Advisory role for Eisai, Amgen, and Pfizer. Dr. Otremba reports no financial conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the Ethical Standards of the Institutional and\/or National Research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}